PROTAC Compound Degrades CDK9 via E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
CDK9 is difficult to therapeutically inhibit due to its similar structure with other kinases, making selective inhibition challenging, especially in cancers like prostate cancer and leukemia where CDK9 dysregulation is prevalent.
Innovation Solution
Conjugation of a CDK9 binding moiety with an E3 ubiquitin ligase binding moiety, such as pomalidomide, to induce ubiquitination and promote degradation of CDK9 through PROTAC technology, utilizing the cellular machinery for protein homeostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional small molecule inhibition is used to target CDK9, then the approach is simple and direct, but selective inhibition is difficult due to similar structure with other kinases
Solution Approach 1:
The patent uses PROTAC technology which introduces an intermediary mechanism - a heterobifunctional molecule that binds both CDK9 and E3 ligase, recruiting cellular ubiquitination machinery as a mediator to achieve selective degradation. This intermediary approach allows selective targeting of CDK9 through its unique binding pocket while leveraging the specificity of E3 ligase interactions, resolving the selectivity issue of traditional small molecule inhibitors.
Solution Approach 2:
The patent changes the fundamental parameter of inhibition mechanism from reversible binding to irreversible proteasomal degradation. By shifting from temporary inhibition to permanent protein degradation, the patent achieves more reliable and sustained CDK9 inhibition while maintaining selectivity through the dual-binding PROTAC structure.
2Reliability
If PROTAC technology is used to target CDK9, then selective degradation is achieved, but the device complexity increases due to heterobifunctional molecule structure
Solution Approach 1:
The PROTAC molecule is segmented into distinct functional domains: a CDK9 binding moiety, a linker region, and an E3 ligase binding moiety. This segmentation allows each component to be optimized independently for its specific binding target while maintaining overall molecular stability and functionality, making the complex structure more manageable and designable.
Solution Approach 2:
The linker region acts as an intermediary component that connects the CDK9 binding moiety and E3 ligase binding moiety. This intermediary segment provides flexibility and spatial arrangement, allowing both binding sites to function simultaneously without interfering with each other, thus managing the complexity of the heterobifunctional structure.
3Reliability
If PROTAC is used to induce ubiquitination and degradation, then therapeutic efficacy is improved, but the loss of CDK9 protein function may have off-target effects
Solution Approach 1:
The PROTAC molecule serves as a selective intermediary that mediates CDK9 degradation through specific molecular recognition. By designing the CDK9 binding moiety to target unique structural features of CDK9's ATP-binding cleft, the patent ensures selective recruitment of CDK9 for degradation while sparing other kinases, thereby reducing off-target effects despite the potent degradation mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively targets and degrades CDK9, offering a potential therapeutic strategy for cancers with CDK9 dysregulation, including prostate cancer and leukemia, by leveraging the ubiquitination and proteasome degradation pathways.
Implementation Method 1
The E3 ligase then recruits an E2 conjugating enzyme to the ternary complex. The E2 is then able to ubiquitinate the target protein, labelling an available lysine residue on the protein
Implementation Method 2
The poly-ubiquitinated target protein is recognized and degraded by the proteasome
Data Source
AI summary
Provided herein are bifunctional compounds that bind cyclin-dependent kinase 9 (CDK9) and/or promote targeted ubiquitination for the degradation of CDK9. In particular, provided are compounds that can bind CDK9, a protein whose dysregulation is implicated in a variety of cancers, and can promote CDK9′s degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon, VHL). The E3 ubiquitin ligase can ubiquitinate CDK9, marking it for proteasomal degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds. Also provided are methods of treating cancer, and methods of promoting the degradation of CDK9 protein by E3 ubiquitin ligase activity in a subject or biological sample by administering a compound or composition described herein.